Connection

Co-Authors

This is a "connection" page, showing publications co-authored by MADELEINE DUVIC and XIAO NI.
Connection Strength

5.906
  1. Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis. Photodermatol Photoimmunol Photomed. 2022 Mar; 38(2):158-168.
    View in: PubMed
    Score: 0.805
  2. CD209+ monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma undergoing extracorporeal photopheresis via the CELLEXTM system. Photodermatol Photoimmunol Photomed. 2020 Jul; 36(4):290-298.
    View in: PubMed
    Score: 0.728
  3. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-?B pathways. Oncotarget. 2017 Sep 22; 8(37):61761-61776.
    View in: PubMed
    Score: 0.599
  4. Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology. 2015 Jul; 4(7):e1011524.
    View in: PubMed
    Score: 0.512
  5. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and S?zary syndrome. Clin Cancer Res. 2015 Jan 15; 21(2):274-85.
    View in: PubMed
    Score: 0.499
  6. Dendritic cells and cutaneous T-cell lymphomas. G Ital Dermatol Venereol. 2011 Apr; 146(2):103-13.
    View in: PubMed
    Score: 0.389
  7. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol. 2008 Nov; 128(11):2631-2639.
    View in: PubMed
    Score: 0.319
  8. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol. 2005 Apr; 124(4):741-50.
    View in: PubMed
    Score: 0.257
  9. New JAK3-INSL3 Fusion Transcript-An Oncogenic Event in Cutaneous T-Cell Lymphoma. Cells. 2023 09 29; 12(19).
    View in: PubMed
    Score: 0.231
  10. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res. 2001 Sep; 7(9):2682-92.
    View in: PubMed
    Score: 0.200
  11. Correction: Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. Oncotarget. 2019 Sep 10; 10(52):5492.
    View in: PubMed
    Score: 0.175
  12. Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. Oncotarget. 2019 May 07; 10(34):3183-3197.
    View in: PubMed
    Score: 0.170
  13. Genomic profiling of S?zary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015 Dec; 47(12):1426-34.
    View in: PubMed
    Score: 0.134
  14. The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed. 2015 Jul; 31(4):184-94.
    View in: PubMed
    Score: 0.128
  15. Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease. J Invest Dermatol. 2013 Aug; 133(8):2098-100.
    View in: PubMed
    Score: 0.111
  16. Increased Twist expression in advanced stage of mycosis fungoides and S?zary syndrome. J Cutan Pathol. 2012 May; 39(5):500-7.
    View in: PubMed
    Score: 0.105
  17. A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol. 2013 Sep; 52(9):1111-4.
    View in: PubMed
    Score: 0.103
  18. Abnormal expression of interleukin-23 in mycosis fungoides/S?zary syndrome lesions. Arch Dermatol Res. 2006 Dec; 298(7):353-6.
    View in: PubMed
    Score: 0.071
  19. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 01; 109(1):31-9.
    View in: PubMed
    Score: 0.071
  20. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005 Nov; 125(5):1045-52.
    View in: PubMed
    Score: 0.067
  21. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/S?zary syndrome cells. J Invest Dermatol. 2004 Aug; 123(2):380-7.
    View in: PubMed
    Score: 0.061
  22. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004 Apr; 50(4):600-7.
    View in: PubMed
    Score: 0.060
  23. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol. 2003 Oct; 121(4):902-9.
    View in: PubMed
    Score: 0.058
  24. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res. 2002 May; 8(5):1234-40.
    View in: PubMed
    Score: 0.052
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.